214 related articles for article (PubMed ID: 22829019)
1. Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells.
Dong Y; Han Q; Zou Y; Deng Z; Lu X; Wang X; Zhang W; Jin H; Su J; Jiang T; Ren H
Mol Cell Biochem; 2012 Nov; 370(1-2):89-102. PubMed ID: 22829019
[TBL] [Abstract][Full Text] [Related]
2. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
6. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
Abouantoun TJ; MacDonald TJ
Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
[TBL] [Abstract][Full Text] [Related]
7. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
9. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
10. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
11. Activation of Aurora A kinase through the FGF1/FGFR signaling axis sustains the stem cell characteristics of glioblastoma cells.
Hsu YC; Kao CY; Chung YF; Lee DC; Liu JW; Chiu IM
Exp Cell Res; 2016 Jun; 344(2):153-66. PubMed ID: 27138904
[TBL] [Abstract][Full Text] [Related]
12. Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition.
Ying M; Wang S; Sang Y; Sun P; Lal B; Goodwin CR; Guerrero-Cazares H; Quinones-Hinojosa A; Laterra J; Xia S
Oncogene; 2011 Aug; 30(31):3454-67. PubMed ID: 21383690
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
[TBL] [Abstract][Full Text] [Related]
15. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Onoyama M; Ohnishi M; Ohara E; Higashi Y; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2013 Feb; 132(4):813-23. PubMed ID: 22821812
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
Matei D; Chang DD; Jeng MH
Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
[TBL] [Abstract][Full Text] [Related]
17. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
20. KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas.
Blom T; Fox H; Angers-Loustau A; Peltonen K; Kerosuo L; Wartiovaara K; Linja M; Jänne OA; Kovanen P; Haapasalo H; Nupponen NN
Int J Cancer; 2008 Aug; 123(4):793-800. PubMed ID: 18506689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
